Coronary heart disease (CHD) is a common form of heart disease. The main
blood vessels supplying the heart (coronary arteries) have difficulty delivering
enough blood, oxygen, and nutrients to the heart muscle. Cholesterol deposits
(plaque) and inflammation in the heart's arteries are often the cause of
coronary artery disease.
Signs and symptoms of CHD occur when the heart does not receive enough
oxygen-rich blood. CHD usually develops over decades. However, as the patient's
arteries narrow, mild symptoms may develop, the most common being chest
pain or shortness of breath. This indicates that the heart is pumping harder
to deliver oxygen-rich blood to the body. Such minor symptoms may go unnoticed
until a serious blockage causes problems or a heart attack occurs.
Angiogenesis, the growth of new collateral vessels, is a natural biological
response to recurrent myocardial ischemia. These newly formed vessels provide
an alternative pathway for blood flow and oxygen delivery to the part of
the patient's heart downstream of coronary artery obstruction. However,
in many patients, including those with recurrent angina, the formation
of coronary collateral vessels is not sufficient to meet the needs of the
heart during periods of stress. Currently available anti-anginal drugs,
which provide symptomatic relief, are usually designed to alter myocardial
oxygen demand or dilate blood vessels to temporarily relieve angina.
Medications can help control a patient's CHD symptoms and prevent or treat
heart disease. Among them,
is considered a realistic treatment option for myocardial ischemia in
specific patient populations. Alferminogene tadenovec is a replication-deficient
human adenovirus serotype 5, which encodes human FGF4, an angiogenic protein
that enhances neointima formation.
Alferminogene tadenovec has the potential to promote improved amelioration
of the disease by harnessing the body's natural healing process in response
to myocardial ischemia (inadequate blood flow and myocardial oxygen supply).
They are designed to promote the heart's natural response to collateral
growth and increase blood flow in the microcirculation. In phase, I and
II clinical trials, the administration of alferminogene tadenovec was well
tolerated and significantly improved treadmill exercise capacity. A phase
III clinical trial is currently evaluating alferminogene tadenovec as a
therapy for myocardial ischemia in women who are not candidates for revascularization.
Alferminogene tadenovec represents a new therapeutic class of biologics,
and Creative BioMart , as always, is focused on its great potential to promote angiogenesis
and increase blood flow in microcirculation. We offer our customers in
the CHD research field a high-quality alferminogene tadenovec product for
the potential treatment of myocardial ischemia. Please feel free to
for the latest news. We are pleased to work with you to find new avenues
for more patients in the field of CHD.